Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.43 Average PT from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTHGet Free Report) has been given an average rating of “Buy” by the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $46.43.

A number of brokerages recently commented on DNTH. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock.

View Our Latest Report on DNTH

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DNTH. Bank of New York Mellon Corp increased its holdings in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after acquiring an additional 72,509 shares during the last quarter. HighVista Strategies LLC bought a new stake in shares of Dianthus Therapeutics in the third quarter worth about $542,000. Charles Schwab Investment Management Inc. lifted its position in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares in the last quarter. State Street Corp boosted its stake in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after buying an additional 413,425 shares during the last quarter. Finally, Barclays PLC grew its holdings in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 6.4 %

NASDAQ DNTH opened at $23.20 on Friday. The company has a 50-day moving average price of $24.77 and a 200-day moving average price of $26.57. Dianthus Therapeutics has a 52 week low of $10.65 and a 52 week high of $33.77. The firm has a market capitalization of $686.65 million, a P/E ratio of -9.28 and a beta of 1.75.

Dianthus Therapeutics (NASDAQ:DNTHGet Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

About Dianthus Therapeutics

(Get Free Report

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Further Reading

Analyst Recommendations for Dianthus Therapeutics (NASDAQ:DNTH)

Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.